

Appl. No. : 08/779,767
 Filed : January 7, 1997

B2 5. (Amended) The [immunomodulating agent of claim 3] composition of Claim 66 wherein said protein fragment or peptide [antagonist is an] comprises a peptide analog of a peptide agonist wherein said peptide agonist capable of activating a T cell response to myelin basic protein.

B3 ~~66~~ 7. (Twice Amended) The composition of Claim 66 wherein the composition [is a chimeric antibody] comprises a fusion protein in which said protein fragment or peptide is covalently joined to said immunoglobulin or portion thereof [in a single molecule].

B4 ~~66~~ 24. (Twice Amended) The composition of claim [23] 67 wherein said [T cell receptor antagonist is an] protein fragment or peptide comprises a peptide analog of a peptide agonist wherein said peptide agonist is capable of activating a T cell response to proteolipid protein.

B5 25. (Amended) The composition of claim 67 wherein said [T cell receptor antagonist is an] protein fragment or peptide comprises a peptide analog of a peptide agonist wherein said peptide agonist is capable of activating a T cell response to myelin basic protein.

B6 ~~66~~ 29. (Twice Amended) The composition of claim [67] 27 wherein said composition comprises a [chimeric antibody] fusion protein in which said protein fragment or peptide is covalently joined to said immunoglobulin or portion thereof [in a single molecule].

~~66~~ 68. (Amended) The composition of Claim 66, wherein said protein fragment or peptide comprising the T cell receptor antagonist is [directly] covalently linked to said immunoglobulin or portion thereof [via a linkage selected from the group consisting of noncovalent linkages and covalent linkages].

B7 ~~66~~ 69. (Amended) The composition of Claim 68, wherein said [T cell receptor antagonist is an] protein fragment or peptide comprises a peptide analog of a peptide agonist wherein said peptide agonist is capable of activating a T cell response to proteolipid protein.

B8 ~~66~~ 72. (Amended) The composition of Claim [68] 67, wherein the composition [is a chimeric antibody] comprises a fusion protein in which said protein fragment or peptide comprising said T cell receptor antagonist is covalently joined to said immunoglobulin or portion thereof [in a single molecule].